Has <i>in vitro</i> allergenicity testing any clinical relevance?

Vandenplas, Yvan; Hauser, Bruno

doi:10.1034/j.1398-9995.2002.1e3129.x

Cited by 7 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…expensive, and most specific screening method for detecting the presence of IgE antibodies in patients who have appropriate exposure histories (Vohlonen et al;Volcheck, 2001). In vitro allergy testing offers another alternative for clinicians in diagnosing and managing allergic disease (Li, 2002;Vandenplas & Hauser, 2002). Today's technology has improved in vitro testing so that it is an efficient and accurate tool in allergen identification.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the Response of Patients Undergoing Both Allergy Skin Testing and in Vitro Allergy Testing With the ImmunoCAP Technology System

Smits

Letz²,

Evans

et al. 2003

Journal of the American Academy of Nurse Practitioners

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating the Response of Patients Undergoing Both Allergy Skin Testing and in Vitro Allergy Testing With the ImmunoCAP Technology System

Smits

Letz²,

Evans

et al. 2003

Journal of the American Academy of Nurse Practitioners

View full text Add to dashboard Cite

show abstract

“…A few human studies have assessed the preventive capacity of pHF in infants at high‐risk of developing CMA, and while some showed the benefit of pHFs in preventing CMA when compared to conventional formulas, [ 11 , 12 , 13 ] Lowe et al. [ 14 ] reported no benefit.…”

Section: Introductionmentioning

confidence: 99%

Camel Milk Cannot Prevent the Development of Cow's Milk Allergy—A Study in Brown Norway Rats

Maryniak

Stage

Ballegaard

et al. 2022

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope: Currently there are no specific recommendations for the use of any particular infant formula in the prevention of cow's milk allergy (CMA). Recently, there has been an increasing interest in alternative infant formulas based on milk proteins from other sources than the cow, including milk from other mammalians such as goat, sheep, donkey, horse, and camel. Whereas these have been studied for their usability in CMA management, there are no studies of their CMA preventive capacity. Thus, the aim of this study is to evaluate whether camel milk can prevent CMA and vice versa. Methods and results: The capacity of camel milk in preventing CMA and vice versa is evaluated in a well-established prophylactic Brown Norway rat model. IgG1, IgE, and IgA responses, allergy elicitation, intestinal and mLN gene expression, and protein uptake are analyzed. The study demonstrates that camel and cow's milk in general has an insignificant cross-preventive capacity. Yet, whereas cow's milk is shown to have a low transient capacity to prevent sensitization and clinically active camel milk allergy, camel milk does not show this effect for CMA. Conclusions: This study suggests that due to lack of cross-tolerance camel milk cannot be used for CMA prevention.

show abstract